


2025

KARNATAKA RADIOLOGY EDUCATION PROGRAM





- Liver: enlarged in size, measuring 29 cm in craniocaudal dimension.
  - A lobulated, relatively circumscribed, heterogeneous lesion of approximate size 10.9 x 15.3 x 14.6 cm (AP x TR x CC) is seen in the liver, involving nearly the entire left lobe
  - Enhancement characteristics:
    - Arterial phase: patchy areas of arterial phase enhancement (early arterial).
    - Portal phase: hyperenhancing compared to the liver parenchyma.
    - Venous phase: nearly isoenhancing to the liver parenchyma.
    - Delayed phase: hypoenhancing/ washout compared to the liver parenchyma.
    - Multiple non-enhancing areas are seen within.
    - No obvious central scar or calcification.
  - Vascular supply and relations: Arterial feeders were identified from left hepatic artery, arising from proper hepatic artery; as well as another feeder from branch of right hepatic artery. Normal hepatic arterial variant anatomy was noted.
  - Features are of concern for hepatocellular carcinoma. Based on age, fibrolamellar variant may be considered.

- A similar morphology lesion is seen in gastrohepatic region measuring approximately 10.5 x 12.4 x 11.3 cm (AP x TR x CC) in size.
- The lesion is supplied by the branches from the common hepatic artery.
- The relations of the lesion are as follows:
  - Anteriorly, abutting the anterior abdominal wall at places, without obvious evidence of infiltration.
  - Posteriorly, showing loss of fat planes with the body of the pancreas, with the MPD being prominent in the distal body and tail region.
  - There is compression of the main portal vein and the spleno-portal confluence.
  - To the left, abutting the body of the stomach.
  - To the right, abutting the small bowel loops.
- Few enlarged nodes are noted along the gastroepiploic vessels.
- Rest of peritoneum was normal. Ovaries were normal.
- This could be a peritoneal deposit with few gastroepiloic lymph nodes.
- The features suggest a malignant pathology considering peritoneal lesion, nodes.
- FNH is not considered as a DD for this case.
- Enhancement pattern does not fit for lymphoma.
- The possibility of GIST was excluded in view of AGE, normal appearing stomach wall and compressed but maintained fat planes.
- Other malignancies occurring in this age (sarcoma, variant of hepatoblastoma, angiosarcoma) are unlikely due to purely solid nature, lack of cystic areas and enhancement pattern.

USG guided biopsy – Fibrolamellar HCC.

#### 1. Distinct Clinical Profile:

- Occurs in adolescents and young adults with no underlying cirrhosis and typically normal AFP.
- Not associated with HBV/HCV, alcohol, or metabolic liver disease.

# 2. Pathologic/Molecular Signature:

- Tumor cells separated by dense lamellar collagen bands.
- Characteristic DNAJB1–PRKACA fusion → highly specific and confirms diagnosis.

## 3. CT Imaging Features:

- Large, well-circumscribed heterogeneous mass, often in left lobe.
- Central stellate scar common and may calcify (seen in ~50%).
- Arterial phase hyperenhancement with progressive/delayed enhancement of the fibrous scar.

#### 4. MRI Characteristics:

- T1: Hypointense tumor and very hypointense scar.
- T2: Tumor mildly hyperintense, but scar is T2 hypointense (important opposite of FNH).
- Hepatobiliary phase (Eovist): Hypointense (no functioning hepatocytes), helping differentiate from FNH.

### 5. Key Differentiator vs FNH:

| Feature           | Fibrolamellar HCC     | FNH               |
|-------------------|-----------------------|-------------------|
| Scar signal on T2 | Dark                  | Bright            |
| HBP signal        | Hypointense           | Iso-/Hyperintense |
| Calcifications    | Common                | Uncommon          |
| AFP               | Usually <b>normal</b> | Normal            |

#### 6. Nodal and Metastatic Behavior:

- Regional lymph node enlargement is common (unlike classic HCC).
- Hematogenous metastases to lung, bone, and peritoneum may occur.

# 7. Treatment Strategy:

- Surgical resection is the treatment of choice; best outcomes when disease localized.
- Transplantation less effective; systemic therapies have limited response, but immunotherapy emerging.

# 8. What to Clearly Report:

- Segmental location, vascular involvement, nodal status, and extrahepatic spread.
- Presence and characteristics of central scar and HBP signal to support diagnosis.

# Contributors

**Dr. M S Kashif**MD, Fellowship in Oncoimaging

**Dr. Zain Sarmast** 

MD, Fellowship in Oncoimaging